anti-CD47/CD20 bispecific antibody (Bristol-Myers Squibb Co)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-CD47/CD20 bispecific antibody (Bristol-Myers Squibb Co)
Drug Alias Namedual anti-CD20/CD47 checkpoint inhibitor (Bristol-Myers Squibb Co)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionCluster of differentiation 47 inhibitorsB-lymphocyte antigen CD20 modulators
TargetsB-lymphocyte antigen CD20Cluster of differentiation 47
Therapy Area/IndicationsHematologic NeoplasmsLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesBristol-Myers Squibb Company
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsLymphoma, Non-Hodgkin
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A